Platelet counts and romiplostim doses by study week in romiplostim-treated splenectomized and nonsplenectomized patients. (A) Median (25th [Q1] and 75th [Q3] percentiles) platelet counts by study week. Median platelet counts in splenectomized and nonsplenectomized patients increased with time on study, although counts varied from week to week and at several time points were lower in splenectomized patients. (B) Median (25th [Q1] and 75th [Q3] percentiles) weekly doses of romiplostim administered during the study. The dose of romiplostim increased through week 7 in splenectomized patients and through week 9 in nonsplenectomized patients. The median dose in splenectomized patients was consistently slightly greater than that in nonsplenectomized patients.